Rapport Therapeutics (RAPP) Treasury Shares (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Treasury Shares for 4 consecutive years, with $295413.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Treasury Shares rose 2012.05% year-over-year to $295413.0; the TTM figure through Mar 2026 stood at $295413.0 (up 2012.05% YoY), while the FY2025 annual figure was $411833.0, down 57.83% from the prior year.
• Treasury Shares slipped to $295413.0 in Q1 2026 per RAPP's latest filing, from $411833.0 in the prior quarter.
• Across five years, Treasury Shares topped out at $100.2 million in Q2 2023 and bottomed at $13987.0 in Q1 2025.
• Historically, Treasury Shares has averaged $33.8 million across 4 years, with a median of $1.0 million in 2024.
• Annual changes were most pronounced in 2025 — Treasury Shares plunged 99.99% — and 2026, when it soared 2012.05%.
• Rapport Therapeutics' Treasury Shares stood at $100.2 million in 2023, then plunged by 99.03% to $976596.0 in 2024, then plunged by 57.83% to $411833.0 in 2025, then declined by 28.27% to $295413.0 in 2026.
• Business Quant data shows RAPP's Treasury Shares at $295413.0 in Q1 2026, $411833.0 in Q4 2025, and $544235.0 in Q3 2025.